We are live on ! Find out more
GPCR icon

Structure Therapeutics

160 hedge funds and large institutions have $2.69B invested in Structure Therapeutics in 2024 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 69 increasing their positions, 35 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

97% more repeat investments, than reductions

Existing positions increased: 69 | Existing positions reduced: 35

75% more funds holding in top 10

Funds holding in top 10: 47 (+3)

16% more capital invested

Capital invested by funds: $2.33B → $2.69B (+$361M)

12% more call options, than puts

Call options by funds: $20.8M | Put options by funds: $18.6M

1.17% more ownership

Funds ownership: 34.64%35.81% (+1.2%)

4% less funds holding

Funds holding: 166160 (-6)

18% less first-time investments, than exits

New positions opened: 27 | Existing positions closed: 33

Holders
160
Holders Change
-6
Holders Change %
-3.61%
% of All Funds
2.3%
Holding in Top 10
7
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+75%
% of All Funds
0.1%
New
27
Increased
69
Reduced
35
Closed
33
Calls
$20.8M
Puts
$18.6M
Net Calls
+$2.16M
Net Calls Change
-$26M
Name Holding Trade Value Shares
Change
Change in
Stake
PC
51
Pier Capital
Connecticut
$5.89M +$1.28M +33,087 +33%
Marshall Wace
52
Marshall Wace
United Kingdom
$5.82M +$2.19M +56,742 +75%
RI
53
RTW Investments
New York
$5.49M
EAM
54
Exome Asset Management
New York
$5.27M +$4.65M +120,165 New
Royal Bank of Canada
55
Royal Bank of Canada
Ontario, Canada
$5.16M +$3.72M +96,091 +448%
IC
56
Ikarian Capital
Texas
$5.06M +$4.45M +115,200 New
WC
57
Wexford Capital
Florida
$4.31M +$193K +5,000 +5%
Bank of America
58
Bank of America
North Carolina
$4.27M +$504K +13,030 +15%
Manulife (Manufacturers Life Insurance)
59
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$3.81M -$291K -7,528 -8%
BBA
60
Baker Bros. Advisors
New York
$3.75M +$3.31M +85,500 New
RAM
61
Readystate Asset Management
Illinois
$3.69M +$3.25M +84,000 New
Barclays
62
Barclays
United Kingdom
$3.56M +$1.58M +40,915 +102%
BPC
63
Banque Pictet & Cie
Switzerland
$3.56M +$3.13M +81,053 New
Hudson Bay Capital Management
64
Hudson Bay Capital Management
Connecticut
$3.14M -$94.5K -2,444 -3%
SCM
65
Silverarc Capital Management
Massachusetts
$3.09M
ACM
66
Altium Capital Management
New York
$3.07M +$2.71M +70,000 New
FAM
67
Fred Alger Management
New York
$2.93M -$8.54M -220,923 -77%
BOCH
68
Blue Owl Capital Holdings
New York
$2.85M +$387K +10,000 +18%
Susquehanna International Group
69
Susquehanna International Group
Pennsylvania
$2.8M -$2.16M -55,837 -47%
Macquarie Group
70
Macquarie Group
Australia
$2.55M
PIM
71
Platinum Investment Management
Australia
$2.51M
Capital Fund Management (CFM)
72
Capital Fund Management (CFM)
France
$2.2M +$1.94M +50,128 New
VOYA Investment Management
73
VOYA Investment Management
Georgia
$2.05M -$578K -14,940 -24%
TI
74
TrueMark Investments
Illinois
$2M +$603K +15,596 +52%
Geode Capital Management
75
Geode Capital Management
Massachusetts
$1.98M +$12.1K +312 +0.7%

GPCR Hedge Fund Activity: Q3 2024 in Review

160 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Structure Therapeutics (GPCR) for Q3 2024, worth a combined $2.69B — up 16% from $2.33B a quarter earlier.

Sellers outnumbered buyers: 33 funds closed out of GPCR and 27 opened new positions — a net loss of 6 holders — while 35 trimmed existing stakes and 69 added.

The largest buyer was Point72 Asset Management, adding an estimated $33.7M. The largest seller was Adage Capital Partners, cutting an estimated $37.2M.

  • 160 institutional investors held Structure Therapeutics (GPCR) as of Q3 2024, down from 166 in Q2 2024.
  • Funds reported $2.69B of Structure Therapeutics stock for Q3 2024, up 16% quarter-over-quarter.
  • 27 funds opened new Structure Therapeutics positions in Q3 2024 and 33 closed out, a net change of -6 holders.
  • The largest Structure Therapeutics buyer in Q3 2024 was Point72 Asset Management, an estimated $33.7M added.
  • The largest Structure Therapeutics seller in Q3 2024 was Adage Capital Partners, an estimated $37.2M sold.

Based on aggregated 13F filings for Q3 2024.